Healthy
Conditions
Keywords
Perindopril, Perindoprilat, Bioequivalence, Pharmacokinetic, Angiotensin-converting enzyme inhibitor
Brief summary
The objective of this study was to find out whether the bioavailability of PT Dexa Medica's formulation of 4 mg perindopril tert-butylamine tablets was equivalent to that of the innovator's product (Prexum® 4 mg, Servier).
Detailed description
The participating subjects were required to have an overnight fast and in the next morning were given orally one tablet of the test drug (Perindopril 4 mg tablets of PT Dexa Medica) or one tablet of the reference drug (Prexum® 4 mg, Servier). Blood samples were drawn immediately before taking the drug (control), and at 20, 40 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 192 hours after drug administration. Three weeks after the first drug administration (washout period), the procedure was repeated using the alternate drug. The pharmacokinetic parameters, including AUCt, AUCinf, Cmax, t max, and t1/2, were determined based on the concentrations of the perindopril parent compound and the metabolite perindoprilat, using high-performance liquid chromatography method with tandem mass spectrometry detector (LC-MS/MS).
Interventions
DRUGPerindopril 4 mg tablets of PT Dexa Medica
Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
DRUGPerindopril 4 mg tablets of Servier
Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Sponsors
Dexa Medica Group
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male and female subjects * Aged 18-55 years inclusive * A body mass index in the range of 18-25 kg/m2 * Able to participate, communicate well with the investigators and willing to give informed consent * Non-smokers * Vital signs (after 10 minutes resting) are within the following ranges: * systolic blood pressure 100-125 mmHg * diastolic blood pressure 60-80 mmHg * pulse rate 60-90 bpm
Exclusion criteria
* Pregnant or lactating women * Known hypersensitivity or contraindication to perindopril * Intake of any prescription drug within 14 days of this study's first dosing day * Intake of any non-prescription drug, food supplement, or herbal medicine within 7 days of this study's first dosing day * History or presence of any liver dysfunction (ALT, alkaline phosphatase, total bilirubin ≥ 1.5 ULN) * History of any bleeding or coagulation disorders * Clinically significant ECG abnormalities * Clinically significant haematology abnormalities * Renal insufficiency (plasma creatinine concentration ≥ 1.4 mg/dL) * Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the study drug * A donation or loss of 500 mL (or more) of blood within 3 months before this study's first dosing day * A positive hepatitis B surface antigen (HBsAg), anti-HCV, and anti-HIV * History of drug or alcohol abuse within 12 months prior to screening of this study * Participation in a previous study within 3 months of this study's first dosing day
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area under concentration-time curve (AUC)of perindopril parent compound | 192 hours | Relative bioavailability (primarily measured by AUCt and AUCinf) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The AUC was measured based on the plasma concentration of perindopril parent compound. |
| Area under concentration-time curve (AUC)of perindoprilat | 192 hours | Relative bioavailability (primarily measured by AUCt and AUCinf) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The AUC was measured based on the plasma concentration of the active metabolite, perindoprilat. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to achieve the peak plasma concentration (tmax)of perindopril parent compound | 192 hours | — |
| Time to achieve the peak plasma concentration (tmax)of perindoprilat | 192 hours | — |
| Peak plasma concentration (Cmax)of perindopril parent compound | 192 hours | Relative bioavailability (secondarily measured by Cmax) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The Cmax was measured based on the plasma concentration of perindopril parent compound. |
| Elimination half-life (t1/2)of perindoprilat | 192 hours | — |
| Elimination half-life (t1/2)of perindopril parent compound | 192 hours | — |
| Peak plasma concentration (Cmax)of perindoprilat | 192 hours | Relative bioavailability (secondarily measured by Cmax) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The Cmax was measured based on the plasma concentration of the active metabolite, perindoprilat. |
Countries
Indonesia
Outcome results
None listed